Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Vaccinomics approach for designing potential peptide vaccine by targeting pyruvate kinase of Madurella mycetomatis
Joint Event on 4th Annual Congress on Infectious Diseases & 5th International Conference on Neglected Tropical & Infectious Diseases
Aya Yusri A Manofali, Ismail M A I, Reem E Talha, Zahra A Neel, Ali A Ali Elamin, Alghzali Altayeb M Abdalla, Alaa I Mohamed, Al Khansa a MOthman, Dalia A M Hamid, Sanaa Bashir, Mohammed Shihabeldin and Mohammed A. Hassan
Omdurman Islamic University, SudanUniversity of Khartoum, SudanUniversity of Medical Science and Technology, SudanOmdurman Islamic University, SudanUniversity of Khartoum, SudanSudan International University, SudanAfrica City of Technology, Sudan
Background: Mycetoma is one of the neglected tropical diseases that considered as a public health problem with socio-economic
impact in several developing countries. It is a chronic progressive destructive suppurative disease can affect any part of the body,
caused by certain fungi (Eumycetoma) or bacteria (Actinomycetoma). Madurella mycetomatis(M mycetomatis) is the predominant
isolated organism causing eumycetoma in Sudan. .There is no effective treatment or a vaccine for it, thus the aim of this study is to
design a peptide-based vaccine against M.mycetomatis infection via in silico approaches, using the immunogenic site Pyruvate kinase
(PK).
Material and Methods: In 26th September 2017 sequence of PK of M. mycetomatis protein was retrieved from the National Center
for Biotechnology Information (NCBI). Immunoinformatics tools were used to predict B and T-cell epitopes and to calculate the
population coverage.
Result and discussion: Two epitopes predicted for b cell (gsypseav, dftkv) as a peptide-based vaccine. for t-cell epitopes, four
epitopes showed high affinity to mhc class i (amaavrsal, yrgvpflf, hlyrgvypf, yrpvcpiim) and high coverage against the whole world
(58.35%, 57.91%, 54.01%, 52.73%) respectively. in mhc class ii, si\x epitopes that interact with the most frequent mhc class ii (fvlstsges,
ivescamaa, lkaensipy, ikwglshai) with high coverage against the whole world (80.93%, 80.02%, 73.12%,70.55%) respectively. moreover,
one shared epitope (lkaensipy) predicted in b-cell, mhc-i, and mhc-ii with high population coverage world combined mhc-i and mhcii
(77.92%) and (57.78%) in sudan. also, four shared epitopes (yrgvypflf, lkaensipy, lyrgvypfl, ikwglshai) between mhc-i and mhc-ii
with epitope set 94.62% worldwide and 92.38% in sudan. till now there is no study was done to predict peptide-based vaccine against
mycetoma infection, so this study will provide a strong base for development of vaccine after in vivo and in vitro studies confirmation
of all this candidate epitopes as effective peptide vaccine.